The intention was to enrich the biological profile of the resulting furochromone carbaldehyde derivatives as potential multi-target drugs against the following targets involved in AD diseases: cholinesterases (AChE and BChE), β-secretase (BACE-1) and lipoxygenases (LOX-5 and LOX-15), as well as for anti-oxidant potential. The gene discussed is BACE1; the disease is Alzheimer disease.